Retapamulin

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Animals1

Outcomes

Cellular senescence

downin human cells1downin mice1

1 study

Retapamulin decreases cellular senescence in human cells.
“improves the senescent phenotype in both intestinal epithelial cells and colonic tissues”
CellsDSS-induced senescence
Retapamulin alleviates DSS-induced ulcerative colitis via direct AMPK activation and modulation of the gut microbiota-metabolite axis
International immunopharmacology17 Nov 2025
Retapamulin decreases cellular senescence in mice.
“Retapamulin (RET) as a novel agent that concurrently mitigates colonic senescence and ameliorates UC symptoms.”
AnimalsDSS-induced senescencecolon
Retapamulin alleviates DSS-induced ulcerative colitis via direct AMPK activation and modulation of the gut microbiota-metabolite axis
International immunopharmacology17 Nov 2025

Latest

1 in 12 months

International Immunopharmacology17 Nov

Retapamulin alleviates DSS-induced ulcerative colitis via direct AMPK activation and modulation of the gut microbiota-metabolite axis

Experiments in miceGut and microbiome

Paper

Retapamulin

Outcomes

Latest

Retapamulin alleviates DSS-induced ulcerative colitis via direct AMPK activation and modulation of the gut microbiota-metabolite axis

Related